The DESTINY-Lung01 Study [80] was a multicenter, international phase II trial of trastuzumab deruxecan (6.4 mg per kg body weight) in patients with metastatic HER2-overexpressing or HER2 mutated NSCLC refractory to standard therapy; ORR was 55% (95% CI 44–65) (50 of 91), with CR in one patient. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.